Hara Capital LLC Acquires New Holdings in Pfizer Inc. (NYSE:PFE)

Hara Capital LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,954 shares of the biopharmaceutical company’s stock, valued at approximately $85,000.

Several other hedge funds also recently modified their holdings of the business. Olistico Wealth LLC acquired a new stake in Pfizer in the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter worth $29,000. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter worth $31,000. Financial Connections Group Inc. acquired a new position in Pfizer in the 2nd quarter valued at $34,000. Finally, ESL Trust Services LLC bought a new position in Pfizer in the 1st quarter worth $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.4 %

Shares of PFE opened at $27.46 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock has a market cap of $155.62 billion, a price-to-earnings ratio of 37.11, a P/E/G ratio of 0.88 and a beta of 0.67. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a 50-day moving average price of $28.96 and a two-hundred day moving average price of $28.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the firm posted ($0.17) EPS. Equities analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.12%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Analyst Ratings Changes

A number of research firms have issued reports on PFE. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.